Ym mis Hydref 2018 gofynnodd Vertex i NICE werthuso Orkambi® ar gyfer cleifion sy’n 2-11 oed.  Ym mis Rhagfyr 2018 gofynnodd Vertex i’r SMC werthuso Orkambi® am yr un grŵp o gleifion.  Ym mis Ionawr 2019 datganodd Vertex nad oedd proses werthuso sefydlog NICE – a ddefnyddiwyd i werthuso meddyginiaethau yn llwyddiannus am ddau ddegawd – yn briodol am eu meddyginiaethau.
In October 2018 Vertex asked NICE to appraise Orkambi® for treating patients aged 2-11. In December 2018 Vertex asked the SMC to appraise Orkambi® for the same group of patients. In January 2019, Vertex stated that NICE’s well-established appraisal process – used to successfully appraise medicines for 2 decades – was not appropriate for their medicines.